Form 4: Plus Therapeutics CFO Acquires Stock Options
SEC Filing
Andrew John Hugh MacIntyre Sims, CFO of Plus Therapeutics, acquired stock options on September 11, 2024.
Summary
- Andrew John Hugh MacIntyre Sims, the Chief Financial Officer of Plus Therapeutics, Inc., filed a Form 4 on September 12, 2024.
- The filing reports a transaction that occurred on September 11, 2024, where Sims acquired 46,074 stock options with an exercise price of $1.26.
- These options vest over four years in equal monthly increments and vest fully upon a change of control event.
- Following the reported transaction, Sims directly owns 46,074 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, and the acquisition of stock options by the CFO is a neutral event.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.
Stakeholder Impact
- The acquisition of stock options by the CFO could potentially align his interests more closely with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of the stock option transaction. |
| 09/11/2034 | Expiration date of the stock options. |
| 09/12/2024 | Date the Form 4 was signed. |
Keywords
Form 4, stock options, insider trading, Plus Therapeutics, PSTV, CFO, Andrew Sims
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.